Australian (ASX) Stock Market Forum

SPL - Starpharma Holdings

Jump to new
I liked the SPL narrative as well. I'm interested to know if Viraleze can inactivate 'flu viruses. This would be handy at work or on public transport for when someone nearby coughs or sneezes repeatedly. A quick squirt up the nose is an easy prophylactic.

The SPL chart also looks bullish even though price has drifted lower since the capital raising was announced. I was alerted by the recent daily high volume bullish bar and since then there's been no selling. (the green rectangle in the charts highlights the 50 - 62% buy zone)

spl2012.PNG
 
Picked for the January Competition.
SPL will get a lot of public interest as a virus preventative. January is a start for some Viraleze marketing tests in Perth. The product is ALREADY acknowledged as virucidal against Covid-19. Also for other killer flu strains.
and...
Its Australian.
 
jbocker said:
Picked for the January Competition.
SPL will get a lot of public interest as a virus preventative. January is a start for some Viraleze marketing tests in Perth. The product is ALREADY acknowledged as virucidal against Covid-19. Also for other killer flu strains.
and...
Its Australian.
Click to expand...
My top pick for yearly competition, same reasons as above.
Also, still hoping approval of other products.
 
My top pick for the 2021 comp.

Viraleze seems to be the right product at the right time and biotechs can win (and lose) big.

I've got to say, Knobby has an eye for these things too!
 
Picked this for the Feb Tipping competition.
Waiting on marketing news for Viraleze.
Will it become a universal Coronavirus preventative?? (including others than Covid-19)
 
Hmmm, you may be looking at a breakout here, MR @jbocker
Nice story, price going well, volume picking up.
I might have to rotate a position into it....
Now, if you get a good announcement any time soon, I will be relinquishing 2nd place to you in monthly comp. :cautious::eek::banghead:


Screenshot_20210205-140904.png
 
Announcement today. Market sensitive.

AZD0466 clinical DEP® program global expansion
• AZD0466 clinical development program expanded to incorporate global clinical trial

• Clinical expansion facilitates patient recruitment into a global Phase 1 study in haematological tumours

• AZD0466 is a highly optimised nanomedicine formulation of AstraZeneca’s novel dual Bcl2/xL inhibitor which utilises Starpharma’s DEP® technology

Melbourne, Australia;
9 February 2021:
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it had been advised by AstraZeneca of its intention to expand the clinical program for AZD0466 to include a multi-centre global Phase 1 study.
The study will recruit patients with acute leukaemias.

Hipefully a win win win for patients, investors and Starpharna.

SSP going for a run.
Giddyup!
 
What I like about Starpharma (these are in my words and I recommend to do you own research.) Disclosure: I hold.
Firstly its a pharmaceutical and as such, these can become massive money earners. Caution: They can also be massive money wasters. Normally huge amounts of time and money is required to get to this position, in Starpharmas case it has 'partnered' with some big pharmaceutical companies to improve cancer drug delivery and drug effectiveness whilst minimising the chronic side effects of some drugs. The drugs are approved and Starpharma is developing a much improved delivery mechanism involving its dendrimer technology and drug combinations. Their product, are dendrimers a polymer technology which I think was originally developed in CSIRO a very well respected Australian scientific research institute. This is what originally attracted me to the company. Fighting cancer. Australian. Nanotech. CSIRO origin (my first job was in CSIRO back in the 70s - fond memories)
These partner pharmaceutical companies are looking for better ways to treat cancer so the market is massive. Starpharma made an announcement just Friday with Merck & Co (probably one of the top 5 pharmaceutical companies worldwide.)

It has also developed some products that are starting to make money, including an effective remedy (VivaGel) for vaginosis and condom coatings that (lab studies only) inactivate things like HIV HSV HPV. The market for both apparently is significant.

Then the discovery and validation last year that SPL7013 a dendrimer compound is virucidal against covid19 and later found to be effective against other deadly caronaviruses (not sure if yet validated for the others). Starpharma is now developing a nasal spray (Viraleze) with the compound to act as a protective measure against Covid-19. It is hoping for release Viraleze this 2021 calendar quarter. I think this is a very exciting time for the company.


As a final note I worry a bit about the vaccine effectiveness and potential side effects, and when you read what the CEO from Merck mentioned last year about vaccines I start to wonder the scope of opportunities that will continue to exist for a product like Viraleze even as the roll out of vaccines begin.
This was posted elsewhere by @Dona Ferentes on July 23 2020;
Ken Frazier, CEO of pharmaceutical giant Merck, was interviewed recently by Professor Tsedal Neeley from Harvard Business School.

Here is a summary of his interview with the following bullet points.
  • Developing a vaccine takes time, a lot of time. The fastest vaccine ever brought to market was for the epidemic parotitis (‘mumps’). It took Merck four years to produce this vaccine.
  • The most recent vaccine created for a large viral outbreak was for the Ebola virus, which took 5.5 years.
  • In the past 25 years there have been only seven truly new vaccines introduced globally. By new, that means that they were effective against a pathogen for which there had previously been no vaccine. Merck has developed four of those seven and the rest of the world three. There has been an enormous amount of work done in the field of prevention. Despite all this work, the world has been trying to develop a vaccine for AIDS since the early 1980s, and so far, without success.
  • Developing a vaccine requires vigorous scientific assessment. Vaccines must be safe, effective, and durable. No one knows if any of the 160 programmes will produce a vaccine that is effective. This vaccine must work on billions of people.
  • Lots of vaccines in the past have stimulated the immune system (just like the Moderna trial vaccine) but ultimately did not confer protection.
  • When politicians suggest there will be a vaccine available by the end of 2020, they are doing the public a “grave disservice”.
  • We do not want to rush the vaccine before rigorous science is done. We do not have a good history of introducing a vaccine in the middle of a pandemic. The swine flu vaccine did more harm than good.
  • While we are working hard on a vaccine, the best preventative measures to limit the spread and infection of COVID-19 are good hygiene, wearing a mask and social distancing.
  • The bigger challenge to developing a vaccine is distributing it to where it is needed most. In a time of ultra-nationalism, countries want to take whatever is available and use it in their own population first rather than offering it to populations globally at greatest risk.
  • Developing a vaccine for 7 billion people has never been done before. Delivering it to 7 billion people is an enormous logistical challenge, especially to those communities who cannot afford it.
  • This is a global pandemic. Unless all of us are safe then none of us is safe.
  • The mobility of the world’s society poses a real problem. The EU has barred Americans travelling to Europe for a reason. Americans are not doing the things required to suppress the epidemic. Americans value liberty. It has been a strong theme through US politics for 200 years, largely because the US has two big oceans protecting it. This virus does not care about liberties. If people exercise liberty at the personal expense of others, then we cannot control this pandemic.
  • America is 4% of the world’s population and 25% of the world’s infections. That’s scary.
  • We need politicians with enough integrity to tell the truth. This time next year we will still be experiencing what we are experiencing now. Be prepared for that.
https://www.firstlinks.com.au/hard-dose-reality-check-vaccines (to acknowledge the source of the above)

OK I will end it there. Do your own research I would suggest to start here.

Starpharma | About Us

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers
starpharma.com starpharma.com
 
Last edited:
qldfrog said:
related : similar product sale ban:
Click to expand...

Viraleze was checked out by Scripps Research in the US. A well respected research institute. They were the people who classified SPL7013 as virucidal to covid19. Starpharma own the rights to SPL7013. SPL7013 is the active component in the Viraleze nasal spray.


The French nasal spray is unrelated to Viraleze, however a failed marketing attempt by others is certainly no help for Starpharmas cause. I trust that the registration process for Viraleze was rigorous enough that it wont suffer a similar fate.
 
Announcement just out.

DEP® HER2-lutetium outperforms in human breast cancer model
• Radiotheranostics1 represent an exciting and rapidly growing area of cancer therapy (radiopharmaceuticals) and diagnosis (radiodiagnostics)

• Starpharma’s DEP® radiopharmaceuticals/diagnostics program has already
generated several candidates including DEP® lutetium, DEP® zirconium, and most recently, DEP® HER2-lutetium

• Starpharma’s newest radiopharmaceutical candidate, DEP® HER2-lutetium, showed complete tumour regression, outperforming Herceptin® labelled with lutetium, in a human breast cancer model

• Starpharma’s earlier candidate, DEP® lutetium - an untargeted dendrimer-lutetium conjugate without a HER2 targeting group - also achieved better efficacy than
Herceptin® labelled with lutetium, including 100% survival, in this model
 

VIRALEZE™ now launched by LloydsPharmacy in the UK​


Starpharma has launched online sales of VIRALEZE™ antiviral nasal spray which is now available for purchase in the UK online at Lloyds Pharmacy.

Following the online launch, Lloyds Pharmacy plan to rollout VIRALEZE™ instore to their 1,400 UK pharmacies in April. VIRALEZE™ will also be available through a further 14,000 independent pharmacies in the UK serviced by McKesson’s AAH wholesale division.

About VIRALEZE™ Antiviral Nasal Spray

VIRALEZE™ Antiviral Nasal Spray was developed by Starpharma (ASX: SPL) and is registered for sale in the UK and Europe. It is an easy-to-use antiviral nasal spray containing 1% w/w astodrimer sodium (SPL7013), shown in laboratory studies to inactivate respiratory viruses, including >99.9% of coronavirus SARS-CoV-2.

VIRALEZE™ binds to and irreversibly inactivates a broad spectrum of viruses. Inactivated viruses are blocked from attaching to cells inside your nose and taking hold. In addition to providing a protective antiviral barrier, VIRALEZE™ provides a moisturising layer to help keep nasal tissue hydrated, protecting it from dryness and damage.

SPL7013 is included in products approved in >40 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.

VIRALEZE™ can be used alongside vaccines, masks, and physical distancing.

Advantages of VIRALEZE™

  • Broad-spectrum, works against multiple strains of SARS-CoV-2 and multiple viruses.
  • Potent antiviral activity against multiple strains of SARS-CoV-2.
  • Virucidal, irreversibly and rapidly inactivating >99.9% of coronavirus/ SARS‑CoV‑2 within one minute[1].
  • Ability to inactivate virus either before or after exposure.
  • Contains a well-tolerated, already marketed active which is not absorbed into the bloodstream.
  • Provides a moisturising and protective barrier to help keep nasal tissue hydrated.
  • Room temperature storage, easy and convenient for regular use.
extracted from https://starpharma.com/news/story/viralezeao-now-launched-by-lloydspharmacy-in-the-uk

disclosure: I hold and I picked it for April 2021 tipping comp. :)
 

Quarterly Cashflow and Activities Report​


I thought it was a good announcement today. I have extracted a couple of interesting points

Their basic business with DEP is progressing very well some good results and it appears more are knocking on Starpharmas door for more programs. The fight with various difficult cancers seemingly is going very well as told in numerous ongoing trials and studies, for example
  • DEP® docetaxel clinical trials continue to progress well, with more than 40 patients now recruited and encouraging efficacy signals observed, including prolonged stable disease and tumour shrinkage in patients with pancreatic, oesophageal, and gastric cancer. These impressive tumour responses include stable disease for up to 40 weeks and significant tumour shrinkage in a heavily pre-treated oesophageal cancer patient, maintained for more than 28 weeks. In addition to the monotherapy of DEP® docetaxel, Starpharma is also recruiting into a study combining DEP® docetaxel with gemcitabine. This study follows compelling data for this combination in pre-clinical human pancreatic cancer models.

The 'distraction' in recent times the Covid buster, Viraleze has taken off with a great start and others to follow
  • On 29 March, VIRALEZE™ was launched in the UK by LloydsPharmacy, initially online and in its first week was the fastest selling product on record on LloydsPharmacy.com. Whilst it is not expected that this rate of sales will necessarily be maintained, both Starpharma and LloydsPharmacy have been very pleased with the launch of the product. VIRALEZE™ has been well received by UK consumers, and the product is now also available at LloydsPharmacy outlets in-store
  • ...
  • As outbreaks of COVID-19 continue around the world, commercial interest in VIRALEZE™ remains strong and discussions for distribution of the product in a number of markets actively continue in parallel. Starpharma is also engaged in discussions with organisations, including various sporting teams which have expressed interest in the product.
  • Starpharma is leveraging the European registration of VIRALEZE™ to expedite further marketing approvals for the product as soon as practicable in other countries, including Australia.
I am keen to hear more of the European countries and good ole Aus, where we seem to be repeatedly having outbreaks and lockdowns, while we are in far better shape than the rest of the world, and I am sure they are watching us, and having another breaker / preventative added into the cycle may be noted as good practice and crack the big commercial markets.

Anyway the cash burn is not massive and dollars are invoiced to come in from viraleze. That is not to mention Vivagel now registered in 45 countries.
More details on all the above here...

Starpharma | {{page_title}}

n/a ... This contains certain forward-looking statements. ... ... ... ... ... ... About Starpharma
starpharma.com starpharma.com
 
SPL is One of my picks for the 2022 tipping Comp.
Their products are useful to everyone especially their nasal spray that has been reported to have anti-COVID properties.
 
I'm picking SPL in the January stock comp. In December they announced a couple of Viraleze launches in Vietnam and Saudi Arabia, which saw the share price round off of a yearly low. I'm expecting this upward momentum to continue through January.
 

Similar threads

System
TRP - Tissue Repair
Replies
3
Views
1K
Dona Ferentes
Dona Ferentes
M
IMMU - Immunicum AB (NASDAQ)
Replies
19
Views
7K
maquet
M
shares
MCM - MC Mining
2 3 4
Replies
67
Views
25K
Dona Ferentes
Dona Ferentes
Gurgler
CYT - Cytopia Limited
Replies
1
Views
4K
moneymajix
moneymajix
O
INEX Pharmaceuticals: Great licensing agreement with Hana Biosciences
Replies
3
Views
5K
ollinbg
O
Top